Karen So

发表

Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies

M. Ferguson, Jonathan A L Duncan, Jeremy S. Bond, 2009, The Lancet.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

R. Plummer, Karen So, T. Yap, 2018, Journal of clinical pharmacology.

Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.

Paul D. Martin, Karen So, Diansong Zhou, 2016, Clinical therapeutics.

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

Karen So, S. Ramalingam, E. Grande, 2019, The Journal of Pharmacology and Experimental Therapeutics.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karen So, A. Dingemans, Yuh-Min Chen, 2018, British journal of clinical pharmacology.

Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

Paul D. Martin, Karen So, E. Lisbon, 2017, Clinical therapeutics.

Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

R. Paschke, Karen So, L. Bastholt, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis

Paul D. Martin, Karen So, G. Mariani, 2016, European Journal of Clinical Pharmacology.

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

Paul D. Martin, Karen So, G. Mariani, 2016, European Journal of Clinical Pharmacology.

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

R. Plummer, Karen So, L. Dirix, 2016, Clinical Therapeutics.

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

A. Ravaud, Karen So, M. Campone, 2020, Cancer Chemotherapy and Pharmacology.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

R. Plummer, Karen So, J. Spicer, 2015, Cancer Chemotherapy and Pharmacology.

Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies

R. Plummer, Karen So, H. Swaisland, 2016, Cancer Chemotherapy and Pharmacology.

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

Karen So, H. Verheul, C. Rolfo, 2015, Advances in Therapy.

Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial

J. Bush, P. Durani, Karen So, 2011, Plastic and reconstructive surgery.

Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial

Jeremy S. Bond, J. Bush, P. Durani, 2010, Plastic and reconstructive surgery.

Absolute Bioavailability of Osimertinib in Healthy Adults

Karen So, K. Thomas, A. Bramley, 2019, Clinical pharmacology in drug development.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting

R. Plummer, Karen So, F. Blackhall, 2017, British Journal of Cancer.

Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.

Karen So, G. Mariani, C. Howes, 2016, Clinical therapeutics.

Effect of food on capsule and granule formulations of selumetinib

Karen So, Sarit Cohen‐Rabbie, R. Goldwater, 2022, Clinical and translational science.

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Paul D. Martin, Karen So, G. Mariani, 2016, Journal of clinical pharmacology.

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Karen So, Diansong Zhou, H. Tomkinson, 2021, Cancer Chemotherapy and Pharmacology.

Interleukin‐10 reduces scar formation in both animal and human cutaneous wounds: Results of two preclinical and phase II randomized control studies

J. Bush, Karen So, T. Mason, 2013, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

Karen So, J. Vansteenkiste, P. Dickinson, 2018, British journal of clinical pharmacology.

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

Karen So, S. Ramalingam, R. Harvey, 2019, Clinical and translational science.

Remote Wound Monitoring of Chronic Ulcers

Jacques Jossinet, Sonja A. Weber, Niall Watermann, 2010, IEEE Transactions on Information Technology in Biomedicine.

Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring

J. Bush, Karen So, T. Mason, 2010, Dermatology research and practice.

Avotermin: emerging evidence of efficacy for the improvement of scarring

J. Bush, Karen So, T. Mason, 2011 .

Effects of interleukin‐10 on cutaneous wounds and scars in humans of African continental ancestral origin

J. Bush, Karen So, A. Metcalfe, 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study

Karen So, M. Akiyama, Y. Nishida, 2023, Neuro-Oncology Advances.

A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib.

Nan Wang, Karen So, Sarit Cohen‐Rabbie, 2022, Clinical Therapeutics.

Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts

Suzanne F. Jones, A. Tinker, A. Oza, 2019, Clinical Trials.

Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial

J. Bush, P. Durani, Karen So, 2011, Plastic and reconstructive surgery.

VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC) stratified by alterations in homologous recombination repair (HRR)-related genes.

A. Tutt, Karen So, L. Ottesen, 2018 .

Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

Karen So, J. Vansteenkiste, P. Dickinson, 2016 .